Serum calcification propensity is associated with HbA1c in type 2 diabetes mellitus

Abstract

Introduction Serum calcification propensity is emerging as an independent predictor for cardiovascular outcomes in high-risk populations. Calcification propensity can be monitored by the maturation time of calciprotein particles in serum (T₅₀ test). A low T₅₀ value is an independent determinant of cardiovascular morbidity and mortality in various populations. Aim was to investigate the T₅₀ and its relationship to type 2 diabetes mellitus. Research design and methods Using nephelometry, serum T₅₀ was cross-sectionally measured in 932 stable patients with type 2 diabetes mellitus (55% male) with a median age of 66 (62–75) years, diabetes duration of 6.5 (3.0–10.2) years and hemoglobin A1c (HbA1c) of 49 (44–54) mmol/mol. Results Serum T₅₀ was normally distributed with a mean value of 261±66 min. In linear regression, serum T₅₀ was lower in women and current smokers. A lower T₅₀ value was found in patients with a higher HbA1c or higher systolic blood pressure, insulin users and patients with a longer history of diabetes. The association with HbA1c was independent of other determinants in multivariable analysis. There was no association between T₅₀ and previous macrovascular events or the presence of microvascular disease. Conclusions Serum calcification propensity is independently associated with glycemic control, suggesting that a lower HbA1c may be associated with better cardiovascular outcomes. Retrospective analysis could not establish an association between a history of macrovascular events and T₅₀, and prospective studies will have to be performed to address this hypothesis. Trial registration number NCT01570140.